379 Initial safety, efficacy, and product attributes from the SURPASS trial with ADP-A2M4CD8, a SPEAR T-cell therapy incorporating an affinity optimized TCR targeting MAGE-A4 and a CD8α co-receptor
David Hong, Jeffrey Clarke, Tanner Johanns, Partow Kebriaei, John Heymach, Ahmed Galal, Samuel Saibil, Adrian Sacher, Francine Brophy, Gareth Betts, Natalie Bath, Spinner William, Alex Tipping, Jessica Tucci, Raymond Luke, Trupti Trivedi, Quan Lin, Jean-Marc Navenot, Paula Fracasso, Karen Miller, Elliot Norry, Mark Dudley, Marcus Butler
Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A231; DOI: 10.1136/jitc-2020-SITC2020.0379
